Bioventix PLC develops and manufactures sheep monoclonal antibodies (SMAs) for use in diagnostic applications, particularly in clinical blood testing. The company focuses on understanding global markets for diagnostic antibodies and engages in research to identify and develop commercially viable products. Bioventix serves customers in the healthcare sector, including laboratories and diagnostic companies, and operates primarily in international markets. Its business model emphasizes long-term value creation through strategic partnerships and the employment of specialized expertise.